Nociception and opioid-induced analgesia in lean (Fa/−) and obese (fa/fa) Zucker rats

Roane, David S.; Porter, Johnny R.

doi:10.1016/0031-9384(86)90156-3

Cited by 50 publications

(34 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Earlier studies demonstrated that female obese Zucker rats with fasting normoglycaemia, aged 17-21 weeks, developed thermal hyperalgesia as indicated by a decreased TFL [34]. In addition, in ZDF rats, thermal hyperalgesia, as indicated by a decrease in paw fanning or licking latency to a noxious thermal (hot plate) stimulus, occurred by 9 weeks of age and was not prevented by the insulin sensitizer rosiglitazone which maintained normoglycaemia [35].…”

Section: Discussionmentioning

confidence: 96%

Time course of pain sensation in rat models of insulin resistance, type 2 diabetes, and exogenous hyperinsulinaemia

Sugimoto

Rashid

Kojima

et al. 2008

Diabetes Metabolism Res

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 96%

Time course of pain sensation in rat models of insulin resistance, type 2 diabetes, and exogenous hyperinsulinaemia

Sugimoto

Rashid

Kojima

et al. 2008

Diabetes Metabolism Res

View full text Add to dashboard Cite

show abstract

“…In 1986, Roane et al showed a defect in the endogenous opioid system in hyperphagic obese Zucker rat [64]. Leptin, an hormone secreted by the White Adipose Tissue (WAT) and hyperexpressed in obese patients, has a decreasing effect on pain threshold if peripherally administered in mice [65].…”

Section: Discussionmentioning

confidence: 99%

Fibromyalgia and obesity: the hidden link

2011

View full text Add to dashboard Cite

Fibromyalgia is a chronic disorder of uncertain etiology, characterized by widespread pain, muscle tenderness, and decreased pain threshold to pressure and other stimuli. Obesity is a well-known aggravating factor for certain rheumatologic conditions, such as knee osteoarthritis. Emerging evidences are exploring the link between obesity and other rheumatic diseases, such as fibromyalgia. Epidemiological data show that fibromyalgia patients have higher prevalence of obesity (40%) and overweight (30%) in multiple studies compared with healthy patients. Several mechanisms have been proposed to explain "the hidden link", but at this time is not possible to ascertain whether obesity is cause or consequence of fibromyalgia. Among mechanisms proposed, there are the following: impaired physical activity, cognitive and sleep disturbances, psychiatric comorbidity and depression, dysfunction of thyroid gland, dysfunction of the GH/IGF-1 axis, impairment of the endogenous opioid system. In this article, we review the scientific evidence supporting a possible link between obesity and fibromyalgia, how obesity influences fibromyalgia symptoms and how fibromyalgia severity can be improved by weight loss. In addition, we analyze the possible mechanisms by which fibromyalgia and obesity interrelate.

show abstract

“…However, conflicting studies report either hypoalgesia 89, 92 or hyperalgesia 78, 112 in similarly aged ZDF. This raises concerns regarding examination of sensory thresholds at just a single age without regard to the developmental stage of diabetes 6, 49, 78, 89, 112 , or omission of ZL controls when multiple ages are assessed 69 . These deficiencies in the literature led us to rigorously evaluate multiple pain-like behaviors in ZDF and ZL at various ages in a well-controlled study.…”

Section: Introductionmentioning

confidence: 99%

“…Hyperglycemia develops within 6–10 wks of age 6, 13, 49, 92 in ZDF but not Zucker Lean (ZL fa/+ ) controls, and is followed by behavioral correlates of PDN, including hypersensitivity to mechanical 6, 25, 69, 78, 92, 101, 112 and thermal 25, 49, 78, 80 somatosensory stimulation. However, conflicting studies report either hypoalgesia 89, 92 or hyperalgesia 78, 112 in similarly aged ZDF.…”

Section: Introductionmentioning

confidence: 99%

Pioglitazone Inhibits the Development of Hyperalgesia and Sensitization of Spinal Nociresponsive Neurons in Type 2 Diabetes

Griggs

Donahue

Adkins

et al. 2016

The Journal of Pain

View full text Add to dashboard Cite

Thiazolidinedione drugs (TZDs) such as pioglitazone are FDA-approved for the treatment of insulin resistance in type 2 diabetes. However, whether TZDs reduce painful diabetic neuropathy (PDN) remains unknown. Therefore we tested the hypothesis that chronic administration of pioglitazone would reduce PDN in Zucker Diabetic Fatty (ZDFfa/fa) rats. Compared to Zucker Lean (ZLfa/+) controls, ZDF developed: (1) elevated blood glucose, HbA1c, methylglyoxal and insulin; (2) mechanical and thermal hyperalgesia at the hindpaw; (3) increased avoidance of noxious mechanical probes in a mechanical conflict avoidance behavioral assay, the first report of a measure of affective-motivational pain-like behavior in ZDF; and (4) exaggerated lumbar dorsal horn immunohistochemical expression of pressure-evoked phosphorylated extracellular signal-regulated kinase (pERK). Seven weeks of pioglitazone (30 mg · kg−1 · d−1 in food) reduced blood glucose, HbA1c, hyperalgesia, and pERK expression in ZDF. This is the first report to reveal hyperalgesia and spinal sensitization in the same ZDF animals, both evoked by a noxious mechanical stimulus that reflects pressure pain frequently associated with clinical PDN. As pioglitazone provides the combined benefit of reducing hyperglycemia, hyperalgesia, and central sensitization, we suggest that TZDs represent an attractive pharmacotherapy in patients with type 2 diabetes-associated pain.

show abstract

Nociception and opioid-induced analgesia in lean (Fa/−) and obese (fa/fa) Zucker rats

Cited by 50 publications

References 21 publications

Time course of pain sensation in rat models of insulin resistance, type 2 diabetes, and exogenous hyperinsulinaemia

Time course of pain sensation in rat models of insulin resistance, type 2 diabetes, and exogenous hyperinsulinaemia

Fibromyalgia and obesity: the hidden link

Pioglitazone Inhibits the Development of Hyperalgesia and Sensitization of Spinal Nociresponsive Neurons in Type 2 Diabetes

Contact Info

Product

Resources

About